Aradigm appoints Juergen Froehlich new chief medical officer

Aradigm has announced the appointment of Juergen Froehlich as Chief Medical Officer. Froehlich is formerly Head of Regulatory Affairs at Vertex Pharmaceuticals where he was responsible for regulatory submissions for Kalydeco.

Both of Aradigm’s inhaled ciprofloxacin formulations, Pulmaquin and Lipoquin, were licensed by Grifols earlier this year.

Aradigm President and CEO Igor Gonda said, “We are delighted that Dr. Froehlich joined our team at this critical juncture when Pulmaquin is entering Phase 3 clinical development for the management of patients with non-cystic fibrosis bronchiectasis. His rich experience in the late stage clinical development and approval of valuable treatments, especially for orphan indications, is a particularly important addition to our expertise.”

Read the Aradigm press release.